Kronik Böbrek Hastalıklarında Kardiyovasküler Risk
Kronik böbrek hastalıklarında risk faktörleri olarakkardiyovasküler hastalık, diyabet, hipertansiyon veobezite gösterilmektedir. Son dönem böbrek hastalığıolanlarda morbidite ve mortalitenin başlıca nedeni vetüm ölümlerin %50’sini kardiyovasküler hastalıklar(koroner kalp hastalığı, serebrovasküler hastalık, periferikvasküler hastalık ve kalp yetmezliği gibi) olşturmaktadır. Diyaliz tedavisi gören 25-35 yaşları aras›ndakikişilerde kardiyovasküler hastal›k 500 katı, 85 yaşve üzerindeki kişilerde ise 5 katı daha fazladır. KBHolan hastalarda GFR azalırken, hormonal, metabolikya/ya da trombojenik faktörlerdeki anormallikler,KVH başlangıcı ve alevlenmesinde önemli bir rol oynamaktadır. Kronik böbrek hastalığı (KBH) olan kiflilerdehem “geleneksel” hem de “geleneksel olmayan”(kronik böbrek hastalığı ile ilgili) KVH risk faktörleriartmıştır. Bu makalede “değiştirilebilir” özelliği nedeniyleKBH’n›n tüm safhalarında geleneksel risk faktörleri(dislipidemi, hipertansiyon, diyabetes mellitus, kötüglisemi kontrol, sigara içme ve bedensel hareketsizlikgibi), risk faktörlerin görülme sıklığı, KVH ile riskfaktörleri arasındaki ilişkileri ve risk faktörlerinin tedavisiüzerinde durulmaktadır.
___
- 1. Center of Disease Control. Prevalence of Chronic Kidney Disease and
Associated Risk Factors. United States, 1999—2004. March 2, 2007 / 56
(08);161-165.
- 2. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney
disease: a public health problem that needs a public health action plan.
Prev Chronic Dis 2006; 3:A57.
- 3. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Ann Intern Med 2003;139:137-47.
- 4. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass
index and CKD in apparently healthy men. Am J Kidney Dis
2005;46:871--80.
- 5. Bruce F. Culleton, Brenda R. Hemmelgarn (2003) Is Chronic Kidney
Disease a Cardiovascular Disease Risk Factor? Seminars In Dialysis 16
(2), 95–100.
- 6. National Kidney Foundation, KDOQI Working Group: The definition,
evaluation and classification of chronic kidney disease. Am J Kidney Dis
2(suppl 1): 2002.
- 7. U.S. Renal Data System: USRDS 1997 Annual Data Report. Bethesda,
MD: National Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, 1997.
- 8. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for
Chronic Kidney Disease: Executive Summary. New York: National Kidney
Foundation, 2002
- 9. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation,
Classification, and Stratification. Part 7. Stratification Of Risk For
Progression Of K›dney D›sease And Development Of Cardiovascular Disease
Guideline 15. Association Of Chronic Kidney Disease With Cardiovascular
Disease. E:\renal failure cv risk\KDOQI CKD Guidelines.htm.
- 10. K/Doqi Clinical Practice Guidelines For Chronic Kidney Disease:
Evaluation, Classification, And Stratification. Part 3. Chron›c K›dney D›-
sease As A Publ›c Health Problem. E:\KDOQI CKD Guidelines.htm
- 11. Levin A. Clinical Epidemiology of Cardiovascular Disease in Chronic
Kidney Disease Prior to Dialysis. Seminars In Dialysis, 2003; 16 (2),
101–105.
- 12. U.S. Renal Data System, USRDS 2002 Annual Data Report, National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, Maryland, 2002.
- 13. Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients
with chronic kidney disease: getting to the heart of the matter. Am J
Kidney Dis 2001; 38: 1398–1407,
- 14. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk
factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327–335.
- 15. KasiskeBL: Hyperlipidemia in patients with chronic renal disease. Am
J Kidney Dis 1998; 32: 142–156.
- 16. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic
heart disease risk after renal transplantation. J Am Soc Nephrol 2000;
11: 1735–1743.
- 17. Saltissi D, Morgan C, Rigby RJ, et al. Safety and efficacy of simvastatin
in hypercholesterolemic patients undergoing chronic renal dialysis.
Am J Kidney Dis 2002; 39: 283–290.
- 18. Summary of the second report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;
269: 3015–3023.
- 19. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure
and elevated serum creatinine level in the United States: findings
from the third National Health and Nutrition Examination Survey
(1988–1994). Arch Intern Med 2001; 161: 1207–1216.
- 20. Buckalew VMJr, Berg RL, Wang SR, et al. Prevalence of hypertension
in 1,795 subjects with chronic renal disease: the modification of diet in
renal disease study baseline cohort. Modification of Diet in Renal
Disease Study Group. Am J Kidney Dis 1996; 28: 811–821.
- 21. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy
on the kidney in patients with diabetes: a meta-regression analysis. Ann
Intern Med 118: 129–138, 1993;
- 22. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor
of cardiovascular outcomes and the impact of ramipril: the HOPE randomized
trial. Ann Intern Med 2001; 134: 629–636.
- 23. The sixth report of the Joint National Committee on prevention,
detection evaluation, and treatment of high blood pressure. Arch Intern
Med 1997; 157: 2413–2446,
- 24. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in
adults with hypertension and diabetes: a consensus approach. National
Kidney Foundation Hypertension and Diabetes Executive Committees
Working Group. Am J Kidney Dis 2000; 36: 646–661.
- 25. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk
factors in renal transplant patients. Nephrol Dial Transplant 1999; 14:
648–654.
- 26. Mailloux LU, Levey AS. Hypertension in patients with chronic renal
disease. Am J Kidney Dis 1998; 32: 120–141.
- 27. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular
disease risk factors in dialysis patients compared with the general population:
the CHOICE study. J Am Soc Nephrol 2002; 13: 1918–1927.
- 28. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology,
therapy, outcomes, and future directions. Am J Kidney Dis
1998; 32: 705–719.
- 29. Salem MM. Hypertension in the hemodialysis population: a survey of
649 patients. Am J Kidney Dis 1995; 26: 461–468.
- 30. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on
cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney
Int 1996; 49: 1379–1385.
- 31. Kawamura M, Fijimoto S, Hisanaga S, et al. Incidence, outcome, and
risk factors of cerebrovascular events in patients undergoing maintenance
hemodialysis. Am J Kidney Dis 1998; 31: 991–996.
- 32. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy
of dialysis. Kidney Int 1992; 41: 1286–1291.
- 33. Coresh J, Longenecker JC, MillerER III, et al. Epidemiology of cardiovascular
risk factors in chronic renal disease. J Am Soc Nephrol 1998;
9: 24–30.
- 34. Kasiske BL, KlingerD. Cigarette smoking in renal transplant recipients.
J Am Soc Nephrol 2000; 11: 753–759.
- 35. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular
disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:
353–362.
- 36. Beto JA, Bansal VK. Interventions for other risk factors: tobacco use,
physical inactivity, menopause, and homocysteine. Am J Kidney Dis
1998; 5(suppl 3):172–184.
- 37. Anderson JE, Jorenby DE, Scott WJ, et al. Treating tobacco use and
dependence: an evidence-based clinical practice guideline for tobacco
cessation. Chest 2002; 121: 932–941.
- 38. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal
Failure, 4th ed.: American College of Physicians, Philadelphia, PA, 1999.
- 39. Stephenson JM, Kenny S, Stevens LK, et al. Proteinuria and mortality
in diabetes: the WHO Multinational Study of Vascular Disease in
Diabetes. Diabet Med 1995; 12: 149–155.
- 40. Effect of intensive therapy on the development and progression of
diabetic nephropathy in the Diabetes Control and Complications Trial.
The Diabetes Control and Complications (DCCT) Research Group. Kidney
Int 1995; 47: 1703–1720.
- 41. Barbosa J, Steffes MW, Sutherland DE, et al. Effect of glycemic control
on early diabetic renal lesions. A 5-year randomized controlled clinical
trial of insulin-dependent diabetic kidney transplant recipients.
JAMA 1994; 272: 600–606.
- 42. Collins AJ, Li S, Ma JZ, et al. Cardiovascular disease in end-stage
renal disease patients. Am J Kidney Dis 2001; 38: 26–29.
- 43. Manske CL. Hyperglycemia and intensive glycemic control in diabetic
patients with chronic renal disease. Am J Kidney Dis 1998; 32:
157–171.
- 44. Painter P, Messer-Rehak D, Hanson P, et al. Exercise capacity in
hemodialysis, CAPD, and renal transplant patients. Nephron 1986; 42:
47–51.
- 45. Sietsema KE, Hiatt WR, Esler A, et al. Clinical and demographic
predictors of exercise capacity in end-stage renal disease. Am J Kidney
Dis 2002; 39: 76–85.
- 46. Surgeon General's report on physical activity and health. From the
Centers for Disease Control and Prevention. JAMA 1996; 276: 522.